CHENGDU, China, Feb. 8, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a pharmaceutical company that develops, manufactures and markets patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, today announced that the senior management will host a conference call to discuss its fiscal year 2011 second quarter financial results at 8:30 a.m. E.T. on Tuesday, February 15, 2011.
Interested parties may access the call by dialing 1-877-941-1427 (toll free) or 1-480-629-9664 (international).
The conference ID is 4410581. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.
A replay will be available from February 15, 2011 till March, 1, 2011 and can be accessed by dialing 1-877-870-5176 (toll free) or 1-858-384-5517 (international). The passcode is 4410581.
This call will be webcast by ViaVid Broadcasting and can be accessed at the following link:
About Tianyin Pharmaceutical
Tianyin Pharmaceutical Co., Inc. (TPI), headquartered at Chengdu, China, specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. TPI has a pipeline of 10 products pending SFDA approval targeting high incidence indications such as cardiovascular disorders. TPI has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about TPI, please visit http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval process, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerBoard DirectorTianyin Pharmaceutical Co., Inc.Web: http://www.tianyinpharma.com Email: Dr.Tong@tianyinpharma.com Tel: +86-28-8551-6696 (Chengdu, China)+86 134 36 550011 (China)+1-949-350-6999 (U.S.)Address:23rd Floor Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China
Copyright©2010 PR Newswire.
All rights reserved